15 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 19 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 15, Terminated 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Carbon-14: new trials by email Literature Review of Carbon-14 trials Research Report on Carbon-14
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test How BI 3034701 is Taken up and Processed by the Body in Healthy Men With Normal Weight or Overweight BI 3034701 (C-14) - Healthy | Phase 1 | Active not recruiting | Boehringer Ingelheim | 8 | 2026-08-24 | 2026-10-13 |
| A Study in Healthy Men to Test How BI 1815368 is Processed in the Body BI 1815368 (C-14), BI 1815368 (C-13) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 8 | 2026-07-16 | 2026-09-15 |
| A Study to Test How BI 1819479 is Taken up and Processed by the Body [14C]BI 1819479, BI 1819479, BI 1819479 (C-14) - Healthy | Phase 1 | Terminated | Boehringer Ingelheim | 7 | 2025-08-04 | 2026-09-30 |
| Tolerance and Effectiveness of C14 on HPV Infection The monoterpenoid zinc tetra-ascorbo-camphorate ("C14"), Distilled water group - HPV-induced Cancers, HPV Infections | Phase 1 / Phase 2 | Not yet recruiting | MGB Pharma | 66 | 2024-11-15 | 2024-11-04 |
| A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body BI 1839100 (C-14) formulation 1, BI 1839100, BI 1839100 (C-14) formulation 2 - Healthy | Phase 1 | Terminated | Boehringer Ingelheim | 8 | 2024-09-30 | 2025-09-23 |
| A Study in Healthy Men to Test How BI 1569912 is Processed in the Body BI 1569912 (C-14), BI 1569912 (C-13) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 8 | 2024-08-26 | 2026-05-22 |
| A Study in Healthy Men to Test How Zongertinib (BI 1810631) is Taken up and Processed by the Body zongertinib (C-14), zongertinib - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 15 | 2023-08-10 | 2025-10-06 |
| A Study in Healthy Men to Test How BI 764198 is Processed in the Body BI 764198 (C-14) (approach 1), BI 764198 (C-14) (approach 2) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 24 | 2023-05-03 | 2026-06-29 |
| A Study in Healthy Men to Test How BI 1291583 is Processed in the Body BI 1291583 mixed with [C-14] BI 1291583 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 8 | 2023-04-24 | 2026-01-21 |
| A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body BI 690517 (C-14), BI 690517 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 14 | 2022-09-19 | 2024-09-20 |
| A Study in Healthy Men to Test How BI 456906 is Processed in the Body BI 456906 (C-14) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 6 | 2022-07-04 | 2022-12-14 |
| Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects 300 mg [C14] CT1812 - Alzheimer Disease | Phase 1 | Completed | Cognition Therapeutics | 8 | 2021-12-31 | 2023-07-21 |
| A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body BI 1015550 (C-14) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 6 | 2021-03-25 | 2025-11-28 |
| A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood BI 1358894, BI 1358894 (C-14) intravenous solution - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 12 | 2020-07-13 | 2025-03-30 |
| A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet BI 730357, BI 730357 mixed with [C-14] BI 730357 BS - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 6 | 2019-01-31 | 2023-07-25 |
| A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body BI 425809 mixed with [C-14] BI425809 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 6 | 2018-09-11 | 2026-03-27 |
| This Study in Healthy Men Tests How the Body Takes up BI 1467335 BI 1467335, BI 1467335 (C-14) intravenous solution - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 12 | 2018-04-10 | 2021-07-08 |
| Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers [C14] selumetinib (oral) - Solid Tumours | Phase 1 | Completed | AstraZeneca | 6 | 2013-10-01 | 2015-06-30 |
| TD-1211 IV/Oral Mass Balance Study TD-1211 IV [C14], TD-1211 PO [C14] - OIC | Phase 1 | Completed | Glycyx Therapeutics | 10 | 2012-11-01 | 2026-05-22 |
Alzheimer Disease (1) · Constipation (1) · Opioid-Induced Constipation (1) · Papillomavirus Infections (1) · Uterine Cervical Neoplasms (1)
Boehringer Ingelheim (15) · AstraZeneca (1) · Cognition Therapeutics (1) · Glycyx Therapeutics (1) · MGB Pharma (1)
Netherlands (13) · United Kingdom (2) · United States (2) · Democratic Republic of the Congo (1) · Hungary (1)
Anthony Caggiano, MD (1) · Stuart Mair, MD (1)
PMID 27751676, PMID 34936055, PMID 36919398, PMID 41348300, PMID 42563128
2018 (2), 2017 (1), 2023 (1), 2025 (1), SB1AG073028 (1)